Applied Therapeutics, Inc.
APLT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.07 | 0.01 | 0.58 |
| FCF Yield | -70.57% | -19.55% | -271.66% | -39.60% |
| EV / EBITDA | -0.41 | -3.63 | -0.17 | -1.69 |
| Quality | ||||
| ROIC | -174.41% | 413.42% | -1,373.80% | -163.34% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.46 | 0.95 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -52.80% | 29.35% | 13.93% | -16.01% |
| Safety | ||||
| Net Debt / EBITDA | 0.74 | 0.77 | 0.18 | 0.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -190.30 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.79 |
| Cash Conversion Cycle | 0.00 | 10.41 | -3,752.63 | -8,782.87 |